Group 1 - The company plans to hold the 2024 annual shareholders' meeting on June 27, 2025, at 14:00, using a combination of on-site and online voting methods [1] - The company has announced the meeting details in a prior notice published on June 5, 2025, on the Shanghai Stock Exchange website [1] Group 2 - To better serve small and medium investors, the company will utilize the Shanghai Stock Exchange Information Network Co., Ltd. to provide a shareholder meeting reminder service [2] - The reminder service will include proactive notifications to shareholders about the meeting and voting procedures via smart SMS [2] - Investors can vote directly through the provided link or use existing trading system platforms if they encounter congestion [2]

证券代码：688065 证券简称：凯赛生物 公告编号：2025-032 上海凯赛生物技术股份有限公司 关于股东大会开设网络投票提示服务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海凯赛生物技术股份有限公司（以下简称"公司"）拟于 2025 年 6 月 27 日 14:00 召开 2024 年年度股东大会，本次会议采用现场投票和网络投票相结合 的 表 决 方 式 ， 详 见 公 司 于 2025 年 6 月 5 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的公司《关于召开 2024 年年度股东大会的通知》（公 告编号：2025-030）。 为更好地服务广大中小投资者，确保有投票意愿的中小投资者能够及时参会、 及时投票，公司拟使用上证所信息网络有限公司（以下简称"上证信息"）提供 的股东大会提醒服务，委托上证信息通过智能短信等形式，根据股权登记日的股 东名册主动提醒股东参会投票，向每一位投资者主动推送股东大会参会邀请、议 案情况等信息。投资者在收到智能短信后，可根据《上市公司股东会 ...

上海凯赛生物技术股份有限公司 2024 年年度股东大会会议资料 证券代码：688065 证券简称：凯赛生物 上海凯赛生物技术股份有限公司 2024 年年度股东大会会议资料 中国·上海 二〇二五年六月二十七日 | | | 上海凯赛生物技术股份有限公司 2024 年年度股东大会会议资料 上海凯赛生物技术股份有限公司 地址：中国（上海）自由贸易试验区蔡伦路 1690 号 5 幢 邮编：201203 电话：86-21-50801916 传真：86-21-50801386 网站：http://www.cathaybiotech.com 上海凯赛生物技术股份有限公司 2024 年年度股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 本次股东大会顺利召开，根据《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司股东大会规则》以及《上海凯赛生物技术股份有限公司章程》等 有关规定，特制定本次股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、请出席大会的股东或其代理人或其他出席者 ...

Core Points - The annual general meeting of Shanghai Cathay Biotech Co., Ltd. is scheduled for June 27, 2025, at 14:00, combining on-site and online voting methods [3][4] - The company reported a significant increase in revenue and net profit for 2024, with total revenue reaching CNY 2,957.91 million, a 39.91% increase year-on-year, and net profit attributable to shareholders amounting to CNY 488.96 million, a 33.41% increase [16][32] - The company plans to distribute a cash dividend of CNY 4.00 per 10 shares, totaling CNY 287.58 million, based on the audited net profit for 2024 [8][9] Meeting Procedures - Attendees must register and confirm their attendance before the meeting starts, and they are required to present their shareholder certificates to enter the venue [2][3] - The meeting will include the election of monitors and counters, the presentation of the independent directors' report, and the discussion of various proposals [4][6][11] Financial Performance - The company achieved a net profit of CNY 488.96 million in 2024, with a significant increase in net profit excluding non-recurring gains and losses, which rose by 51.60% to CNY 464.73 million [16][32] - The total assets of the company reached CNY 19.02 billion, reflecting a stable financial position [32] Strategic Developments - The company has successfully introduced CNY 5.915 billion in funding through a directed issuance of shares to enhance its business development [18] - A strategic cooperation agreement was signed with Hefei Municipal Government and China Merchants Innovation Technology Group to establish a synthetic biological materials industry cluster [18][28] Governance and Compliance - The board of directors and the supervisory board have actively fulfilled their responsibilities, ensuring compliance with relevant laws and regulations [19][25] - The company has maintained a high standard of information disclosure, achieving an A-level rating for its disclosure practices in the Shanghai Stock Exchange [23][26]

Core Insights - The Ministry of Industry and Information Technology and the National Development and Reform Commission have initiated a program to cultivate over 20 pilot platforms for biomanufacturing by 2027, aiming to facilitate industrial scale-up [1] - Significant technological breakthroughs and industrial layouts are emerging in the biomanufacturing sector, with advancements in areas such as polysulfone plastic recycling and wool sterol synthesis [1] - The synergy between policy support and industrial development is accelerating the transition of biomanufacturing from laboratory research to large-scale industrialization, showcasing a vibrant development chain of "technological breakthroughs - policy support - capital influx" [1] Industry Developments - Synthetic biology is reshaping production models in biomanufacturing, enabling tasks that traditional biotechnologies cannot achieve, while also providing more efficient and environmentally friendly biosynthesis solutions [1] - Companies like Huaxi Biological and Yikole are extending their capabilities in synthetic biology, with Huaxi focusing on the supply chain of hyaluronic acid and Yikole leveraging CRISPR-Cas9 technology for precise gene editing [2][3] - The integration of synthetic biology with traditional industries is seen as a means to enhance productivity and create new growth opportunities, rather than a conflict [4] Technological Innovations - Companies are developing comprehensive systems in synthetic biology, focusing on tool, platform, and product integration, with significant advancements in production efficiency [3] - AI is playing a crucial role in enhancing research efficiency in synthetic biology, with companies establishing AI teams to optimize data collection and algorithm development [7] - The use of AI in the design and testing phases of synthetic biology is expected to significantly reduce research timelines and costs, improving overall productivity [7] Market Trends - The biomanufacturing industry is experiencing a wave of policy support, with various local governments implementing initiatives to promote the industrialization of synthetic biology [8] - The market for biomanufacturing in China is projected to approach 1.8 trillion yuan by 2030, indicating substantial growth potential [8] - Recent financing trends show an acceleration in investments in domestic synthetic biology companies, with nearly a hundred firms securing new funding at the beginning of 2025 [8] Future Outlook - The synthetic biology sector is anticipated to undergo rapid technological iterations and deeper application expansions in the next 3-5 years, driven by AI advancements [9] - Companies are encouraged to focus on quality improvement and original design rather than mere scale expansion, to avoid resource wastage and industry chaos [9] - The industry is expected to face dual challenges in technology transfer and industrialization, particularly in constructing microbial cell factories and overcoming engineering challenges in fermentation and purification [10]

Core Viewpoint - The chemical new materials industry is expected to enter a rapid growth phase driven by policy support, industrial transformation, and increasing domestic demand for high-performance materials in sectors such as semiconductors, electronics, and renewable energy [2][11][12]. Group 1: Industry Growth and Market Potential - The global chemical new materials market was valued at approximately $370 billion in 2019 and is projected to reach $480 billion by 2025, with a CAGR of about 4.4% [3][16]. - The domestic market for chemical new materials is estimated to grow from approximately 900 billion yuan in 2019 to 1.5 trillion yuan by 2025, reflecting a CAGR of 8.6% [3][25]. - The demand for chemical new materials is expected to continue growing due to the transformation and upgrading of industries such as semiconductors, electronics, and renewable energy [3][25]. Group 2: Policy Support and Technological Advancements - The Chinese government has increased support for high-end manufacturing and new materials since the US-China trade tensions began in 2018, with policies aimed at promoting self-sufficiency in the supply chain [2][12]. - The Ministry of Industry and Information Technology released a directory in December 2021 that includes over 300 types of new materials, highlighting the government's commitment to advancing this sector [4][12]. - Domestic companies have significantly increased their R&D investments, with a reported 17 billion euros in 2019, reflecting a CAGR of 36% from 2014 to 2019 [4][27]. Group 3: Domestic Industry Landscape - The domestic chemical new materials industry has a strong foundation, with a market value of approximately 600 billion yuan in 2019, but still relies heavily on imports for high-end products [17]. - Key domestic players such as Wanhua Chemical, Hualu Hengsheng, and Jinhai Technology are making strides in the new materials sector through innovation and technology adoption [33]. - The industry is characterized by a significant opportunity for domestic substitution, particularly in high-end polyolefins, engineering plastics, and functional films, where self-sufficiency remains low [17][19]. Group 4: Emerging Opportunities and Trends - The demand for high-performance fibers, films, and electronic chemicals is expected to grow rapidly, driven by advancements in sectors like renewable energy and electronics [5][25]. - Emerging materials such as aerogels and biobased materials are gaining traction, with domestic companies positioned to capture early market share in these innovative fields [5][19]. - The lifecycle of many new materials in China is still in the early stages, indicating substantial room for growth and development compared to more mature markets in developed countries [19][20].

证券代码：688065 证券简称：凯赛生物 公告编号：2025-028 上海凯赛生物技术股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/22 ， 由 原 控 | | 公 | 司 | | 股 | 股 | 东 | Cathay | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | Industrial Biotech Ltd.提议 | | | | | | | | | | 回购方案实施期限 | 2024 年 月 21 日~2025 年 | 10 | | | 10 | 月 | 20 | 日 | | | 预计回购金额 | 1,000万元~2,000万元 | | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | | | □用于转换公司可转债 | | | | | | | | | | | □ ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-031 上海凯赛生物技术股份有限公司 续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：天健会计师事务所（特殊普通合伙） 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2025 年 6 月 4 日 召开第二届董事会第三十二次会议，审议通过了《关于续聘 2025 年度审计机构 的议案》，公司拟继续聘任天健会计师事务所（特殊普通合伙）（以下简称"天健"） 为公司 2025 年度财务及内部控制审计机构，该议案尚需提请公司 2024 年年度股 东大会审议。现将相关事宜公告如下： 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | --- | --- | --- | | 成立日期 | 2011 年 7 月 18 日 | 组织形式 特殊普通合伙 | | 注册地址 | 浙江省杭州市西湖区西溪路 | 128 号 6 楼 | | 首席合 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-030 上海凯赛生物技术股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 27 日 至2025 年 6 月 27 日 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 召开日期时间：2025 年 6 月 27 日 14 点 00 分 召开地点：上海市闵行区绿洲环路 396 弄 11 号 9 楼会议室 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 股东大会召开日期：2025年6月27日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 证券代码：688065 证券简称：凯赛生物 公告编号：2025-029 上海凯赛生物技术股份有限公司 第二届监事会第二十六次会议决议公告 表决结果：3票同意；0票反对；0票弃权。 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《关于 续聘会计师事务所的公告》（公告编号：2025-031）。 特此公告。 上海凯赛生物技术股份有限公司 监 事 会 2025 年 6 月 5 日 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2025 年 5 月 25 日向全 体监事以邮件方式发出会议通知，并于 2025 年 6 月 4 日 15:00 以通讯会议的方式召 开第二届监事会第二十六次会议。本次会议由监事会主席张国华主持，会议应到 3 人， 实到 3 人。本次会议的召集、召开符合《中华人民共和国公司法》等法律、法规、规 章、规范性文件和《公司章程》的有关规定，表决形成的决议合法、有效。 二、监事会会议审议情况 审议通过《关于续 ...